Zobrazeno 1 - 10
of 11
pro vyhledávání: '"F A, Chrzanowski"'
Autor:
F. A. Chrzanowski, Kaleem Ahmad
Publikováno v:
Drug Development and Industrial Pharmacy. 43:421-431
Salts of linogliride with reduced solubilities were prepared and evaluated as potential candidates for extended-release oral dosage forms. A once-daily dose of 300-800 mg was intended. Seven acids were selected: p-acetamidobenzoic, benzoic, p-hydroxy
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0710ca093b56f11486f26a53c69ee7ac
https://doi.org/10.1080/03639045.2016.1257019
https://doi.org/10.1080/03639045.2016.1257019
Autor:
F. A. Chrzanowski
Publikováno v:
AAPS PharmSciTech. 9:646-650
Two numerical methods, Decision Analysis (DA) and Potential Problem Analysis (PPA) are presented as alternative selection methods to the logical method presented in Part I. In DA properties are weighted and outcomes are scored. The weighted scores fo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9ef94485f4e1441b23e1b6cab8af9f12
https://doi.org/10.1208/s12249-008-9069-1
https://doi.org/10.1208/s12249-008-9069-1
Autor:
F. A. Chrzanowski
Publikováno v:
AAPS PharmSciTech. 9:635-638
The physical-chemical properties of interest for controlled release (CR) dosage form development presented are based on the author's experience. Part I addresses selection of the final form based on a logical progression of physical-chemical properti
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7182693b9fcfdc4ae1d3bf734f501b3f
https://doi.org/10.1208/s12249-008-9068-2
https://doi.org/10.1208/s12249-008-9068-2
Autor:
F. A. Chrzanowski
Publikováno v:
AAPS PharmSciTech. 9(2)
Practical examples of preformulation support of the form selected for formulation development are provided using several drug substances (DSs). The examples include determination of the solubilities vs. pH particularly for the range pH 1 to 8 because
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::00c547dbfb7dbe8949863eb6f4c599be
https://pubmed.ncbi.nlm.nih.gov/18431656
https://pubmed.ncbi.nlm.nih.gov/18431656
Publikováno v:
The Journal of burn carerehabilitation. 21(1 Pt 1)
The cellular mechanisms by which topical cyclosporine A (tCsA) induces site-specific immunosuppression were investigated. Experiments were designed to elucidate how cyclosporine A (CsA) suppresses activated immunocytes in animals that are undergoing
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::d870d1856ab993f82d95788efc8ef14a
https://pubmed.ncbi.nlm.nih.gov/10661533
https://pubmed.ncbi.nlm.nih.gov/10661533
Publikováno v:
Biochemical Medicine. 11:26-31
A method is presented for the analysis of theophylline in human serum. The method is specific with no interference from theophylline metabolites, ephedrine, hydrocortisone, or caffeine and their metabolites. It is sensitive to approximately 1 μg/ml
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::55e152d6a77a316f10266a968c8d9207
https://doi.org/10.1016/0006-2944(74)90091-x
https://doi.org/10.1016/0006-2944(74)90091-x
Autor:
F. A. Chrzanowski, J. E. Mills, C. Y. Ko, V. Paragamian, Walkling Wd, J. N. Plampin, R. S. Egan
Publikováno v:
Drug Development and Industrial Pharmacy. 10:241-258
Fenoctimine sulfate was demonstrated to exist in two distinct crystalline forms, i.e., form A (low melting, 0.5 mole water of hydration), and form B (high melting, anhydrous). These forms can exist separately, in crystalline mixtures with each other,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e274f6b82abcb1f0e53665aca48299d4
https://doi.org/10.3109/03639048409064648
https://doi.org/10.3109/03639048409064648
Publikováno v:
Journal of parenteral science and technology : a publication of the Parenteral Drug Association. 39(1)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::18970cf9633d7e60de9b89279faa4992
https://pubmed.ncbi.nlm.nih.gov/3973803
https://pubmed.ncbi.nlm.nih.gov/3973803
Publikováno v:
Journal of parenteral science and technology : a publication of the Parenteral Drug Association. 36(5)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::b5f1c919c6f9a5ab92c5fee4fa110cb9
https://pubmed.ncbi.nlm.nih.gov/6985455
https://pubmed.ncbi.nlm.nih.gov/6985455
Publikováno v:
Chemischer Informationsdienst. 16
The pKa values for butaclamol (1), 1,2,3,5,6,10b beta-hexahydro-6 alpha-phenylpyrrolo[2,1-alpha]isoquinoline (2, McN-4612-Y), and 2-tert-butyl-1,3,4,6,7,11b beta-hexahydro-7 beta-phenyl-2H-benzo[alpha]quinolizin-2 alpha-ol (3, McN-4171) were determin
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::18c0fe619a704bae1b9d6b503bf85aab
https://doi.org/10.1002/chin.198532380
https://doi.org/10.1002/chin.198532380